Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170469 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed
A Phase 2 study of Bacillus Anthracis (Anthrax), sponsored by PharmAthene UK Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
- 16
- Study locations
NCT00170469: Completed Phase 2 study of Bacillus Anthracis (Anthrax), sponsored by PharmAthene UK Limited.
NCT00170469 is a Phase 2 study of Bacillus Anthracis (Anthrax) that has completed, run by PharmAthene UK Limited. The registered enrollment target is 226 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% higher). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00170469, a Phase 2 study of Bacillus Anthracis (Anthrax), has completed, sponsored by PharmAthene UK Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an immune response will be evaluated.
Conditions Studied
Interventions
- BIOLOGICAL AVA
- BIOLOGICAL rPA vaccine containing alhydrogel
Study Locations (16)
Florida
- Florida Medical Research Institute - Gainesville
- Accelovance - Melbourne
- Miami Research Associates - South Miami
Alabama
- Greater Huntsville Family Practice, PC - Huntsville
- Discovery Alliance, Inc. - Mobile
Oklahoma
- Accelovance - Oklahoma City
- Lynn Health Science Institute - Oklahoma City
Texas
- PharamTex Research, Inc. - Amarillo
- Accelovance - Houston
Virginia
- Metropolitan Research - Fairfax
- Carilion Medical Associates - Galax
California
- Accelovance - San Diego
District of Columbia
- Accelovance - Washington D.C.
Illinois
- Accelovance - Orland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 2 |
What the finished NCT00170469 record still lists
NCT00170469 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% higher).
The record links to 1 condition, with Bacillus Anthracis (Anthrax) appearing as the primary indexed condition, and to 2 interventions - of which AVA is the first listed.
NCT00170469 lists 16 locations in 10 states (Florida, Alabama, Oklahoma).
Frequently Asked Questions
What is clinical trial NCT00170469 about?
NCT00170469 is a clinical study titled "Safety, Tolerability and Immunogenicity of Recombinant Anthrax Vaccine Compared With Anthrax Vaccine Adsorbed". This is a dose ranging study comparing different vaccine schedules of rPA vaccine, for Anthrax, to the licensed dose of AVA, another Anthrax vaccine. Safety and the capability to induce an immune response will be evaluated.
What is the current status of trial NCT00170469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2005-03. Estimated completion is 2007-02.
What conditions does trial NCT00170469 study?
This clinical trial studies the following conditions: Bacillus Anthracis (Anthrax).
What interventions are being tested in trial NCT00170469?
The interventions under investigation include: AVA (BIOLOGICAL), rPA vaccine containing alhydrogel (BIOLOGICAL).
Who is sponsoring clinical trial NCT00170469?
This trial is sponsored by PharmAthene UK Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00170469 being conducted?
This trial has 16 study locations across Alabama, California, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00170469's enrollment target sits among peer trials
226 267th of 2000 higher than 1,734 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia